Navigation Links
BioMS Medical reports results of exploratory phase II trial of dirucotide in relapsing remitting multiple sclerosis
Date:1/30/2009

Toronto Stock Exchange Symbol: MS

EDMONTON, Jan. 30 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced results from MINDSET-01, an exploratory phase II clinical trial evaluating dirucotide in patients with relapsing-remitting MS. The lead clinical development program for dirucotide is for secondary progressive MS where it is being evaluated in two ongoing phase III trials in the United States, Canada and Europe, with results from the Canadian and European MAESTRO-01 trial expected in the second half of 2009.

The results of the MINDSET-01 study showed that dirucotide did not meet its primary endpoint, annualized relapse rate or associated secondary MRI endpoints. Dirucotide did meet certain secondary endpoints related to the progression of the disease, including mean change from baseline in the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Functional Composite (MSFC) score. The EDSS is a method of quantifying disability in MS, while the MSFC evaluates additional functional parameters. Measuring changes in EDSS and MSFC are primary and secondary outcomes in the ongoing phase III secondary progressive MS trials.

The data also showed that dirucotide was generally well tolerated. The most common side effects reported were redness and burning sensation at the injection site. No patients withdrew due to adverse events.

BioMS and its partner Eli Lilly & Company (Lilly) will continue to analyze the results of this exploratory phase II trial. Under the terms of the licensing agreement with Lilly, no milestone payment was associated with this trial.

"We are encouraged that dirucotide has demonstrated an effect on certain clinical measures of disease progression, this time in the earlier form of the disease," said Kevin Giese, President and CEO of BioMS Medical. "Dirucotide was developed as a potential treatment f
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. BioMS Medical recognized at Scrip Awards 2008
2. BioMS Medical Announces Third Quarter 2008 Results
3. BioMS Medical to present at Rodman and Renshaw Annual Healthcare Conference
4. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
5. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
6. BioMS Medical announces receipt of milestone payment from Eli Lilly and Company
7. BioMS Medical to present at Sachs Associates Biotech in Europe Forum
8. BioMS Medical to present at UBS Global Life Sciences Conference
9. BioMS Medicals lead drug, dirucotide (MBP8298) for the treatment of multiple sclerosis, receives fast track designation from FDA
10. BioMS Medical announces its intention to renew a normal course issuer bid
11. BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2015)... Boston, MA (PRWEB) April 28, 2015 ... the science of the little-known and incurable disease, ... awarded $485,840 in grants to new projects in the ... and children around the world. , The FSH Society’s ... proposals for the grants. They awarded monies to projects ...
(Date:4/28/2015)... (PRWEB) April 28, 2015 CargoSense, ... company focused on supply chain logistics, today announced ... its seed round, bringing total investment proceeds to ... early stage venture capital firms IrishAngels and Middleburg ... Innovative Technology, also participated in the round. ...
(Date:4/28/2015)... Pittsburgh, PA (PRWEB) April 28, 2015 ... its participation in the upcoming Labroots virtual ... May 13-14, 2015. The theme of this ... genomics topics such as RNAi, Next-generation sequencing, ... epigenetics, mapping, exomes, genomic medicine, human Genome ...
(Date:4/28/2015)... April 28, 2015 Showcasing continued ... a relationship marketing company that provides scientifically advanced, ... of the Direct Selling Association (DSA) by the ... minimum one-year review period, the DSA confirmed that ... and expectations of the association: to ensure that ...
Breaking Biology Technology:FSH Society Awards $485,000 in Grants for Research Dedicated to FSH Muscular Dystrophy 2FSH Society Awards $485,000 in Grants for Research Dedicated to FSH Muscular Dystrophy 3FSH Society Awards $485,000 in Grants for Research Dedicated to FSH Muscular Dystrophy 4CargoSense Completes Seed Round Offering By Raising $2.5 Million 2CargoSense Completes Seed Round Offering By Raising $2.5 Million 3CargoSense Completes Seed Round Offering By Raising $2.5 Million 4Pittcon Announces Plans to Exhibit at the Annual Labroots Genetics and Genomics Virtual Event 2Pittcon Announces Plans to Exhibit at the Annual Labroots Genetics and Genomics Virtual Event 3Nerium International Receives Direct Selling Association Membership 2Nerium International Receives Direct Selling Association Membership 3
... of our nation,s long-term clean-energy future, but the technology ... Japan,s recent Fukushima disaster. Indeed, many nations have called ... are operating safely. In the United States, ... percent of the electricity from emission-free sources, including renewable ...
... Mediabrands, IPG Media Lab and Affectiva today announced, ... results of the first annual Neuromarketing Awards. Utilizing ... record and measure viewers, tacit, non-verbal response to ... features are established and are then measured and ...
... ,   The randomised, ... efficacy and safety of,the monoclonal antibody rituximab (RTX) ... that in patients with,severe AAV a single course ... period of 18 months proved to be as ...
Cached Biology Technology:Berkeley scientists pioneer nanoscale nuclear materials testing capability 2The IPG Media Lab and Affectiva Announce Winners of First Annual Neuromarketing Awards 2The IPG Media Lab and Affectiva Announce Winners of First Annual Neuromarketing Awards 3ERA-EDTA Congress 2011: Late Breaking Clinical Trials I 2
(Date:4/10/2015)... , April 10, 2015 ... addition of the "Security Competitive Profiles - NEC" ... http://photos.prnewswire.com/prnh/20130307/600769) , NEC will continue to supply ... to the market, with a company focus on the ... anticipated. Winning opportunities in the ...
(Date:4/6/2015)... Conn. , Apr. 6, 2015 NXT-ID, ... "Company"), a biometric authentication company focused on the ... has filed provisional patent 62/143028 for ... COMMUNICATIONS AND ENERGY TRANSFER  NXT-ID introduces a ... payments. This patent surrounds the use of miniature ...
(Date:4/2/2015)... Sweden , April 2, 2015 ... for Q1 2015 attributed to somewhat higher than 125 ... in the year-end report 2014 that revenues for Q1 ... that the company reported for Q4 2014. The operating ... to be negative. The complete interim report will as ...
Breaking Biology News(10 mins):NEC Security Competitive Profile 2015 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4Fingerprint Cards Revises Revenues for Q1 2015 2
... , This release is available in ... the Tulane University School of Medicine, in New ... major component of black seed oil ( Nigella ... aggressive prostate cancer (PCa) cell lines, in vitro. ...
... widely known for precisely positioning and sculpting various organs ... that could be useful for understanding the explosive growth ... are being born with genital and urinary tract malformations. ... Communications , researchers at the University of Florida say ...
... The International Institute for Species Exploration at Arizona State University ... calendar year. The list for 2009 was published to coincide ... of Carl Linnaeus. It contains only two new plant species, ... Journal of the Linnean Society . Nepenthes ...
Cached Biology News:Thymoquinone induced oxidative stress targets highly aggressive prostate cancers 2Sluggish cell division may help explain genital defects 2Sluggish cell division may help explain genital defects 3Sluggish cell division may help explain genital defects 4Rare carnivorous plant on top 10 list of newly discovered species 2